Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
38M
-
Shares change
-
-2.24M
-
Total reported value, excl. options
-
$1.3B
-
Value change
-
-$41.7M
-
Put/Call ratio
-
2.02
-
Number of buys
-
60
-
Number of sells
-
-67
-
Price
-
$34.31
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2019
197 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2019.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38M shares
of 108M outstanding shares and own 35.28% of the company stock.
Largest 10 shareholders include FMR LLC (6.32M shares), VANGUARD GROUP INC (4.22M shares), BlackRock Inc. (3.91M shares), Bellevue Group AG (2.37M shares), Consonance Capital Management LP (1.98M shares), WASATCH ADVISORS INC (1.78M shares), DIMENSIONAL FUND ADVISORS LP (1.7M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.29M shares), STATE STREET CORP (1.11M shares), and MORGAN STANLEY (907K shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.